# Kobe City Medical Center General Hospital

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/kobe-city-medical-center-general-hospital/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 31.5 |
| Citations | 298,884 |
| City | Kobe |
| Country | JP |
| Description | Kobe City Medical Center General Hospital is a research organisation in Kobe, JP. OpenAlex records 7,153 works and 298,884 citations for it. 1,283 researchers list it as their most recent affiliation. |
| Homepage | http://chuo.kcho.jp/foreign_page/eng/eng_index.html |
| OpenAlex ID | https://openalex.org/I4210161700 |
| Researchers | 1,283 |
| ROR ID | https://ror.org/04j4nak57 |
| Type | healthcare |
| Works | 7,153 |

## University papers

- [BAP1 loss defines a new class of renal cell carcinoma](https://scholariq.org/papers/bap1-loss-defines-a-new-class-of-renal-cell-carcinoma/)
- [Prevalence of Cardiovascular Disease and Its Risk Factors in Primary Aldosteronism](https://scholariq.org/papers/prevalence-of-cardiovascular-disease-and-its-risk-factors-in-primary/)
- [A Validated Tumorgraft Model Reveals Activity of Dovitinib Against Renal Cell Carcinoma](https://scholariq.org/papers/a-validated-tumorgraft-model-reveals-activity-of-dovitinib-against-renal-cell/)
- [Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab](https://scholariq.org/papers/incidence-features-and-prognosis-of-immune-related-adverse-events-involving-the/)
- [Interplay Between pVHL and mTORC1 Pathways in Clear-Cell Renal Cell Carcinoma](https://scholariq.org/papers/interplay-between-pvhl-and-mtorc1-pathways-in-clear-cell-renal-cell-carcinoma/)
- [Exposure–Toxicity Relationship of Sorafenib in Japanese Patients with Renal Cell Carcinoma and Hepatocellular Carcinoma](https://scholariq.org/papers/exposure-toxicity-relationship-of-sorafenib-in-japanese-patients-with-renal-cell/)
- [Obesity as a Key Factor Underlying Idiopathic Hyperaldosteronism](https://scholariq.org/papers/obesity-as-a-key-factor-underlying-idiopathic-hyperaldosteronism/)
- [Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer](https://scholariq.org/papers/clinical-utility-of-androgen-receptor-gene-aberrations-in-circulating-cell-free/)
- [Decreased expression of lysophosphatidylcholine (16:0/OH) in high resolution imaging mass spectrometry independently predicts biochemical recurrence after surgical treatment for prostate cancer](https://scholariq.org/papers/decreased-expression-of-lysophosphatidylcholine-16-0-oh-in-high-resolution/)
- [Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies](https://scholariq.org/papers/systematic-chemical-screening-identifies-disulfiram-as-a-repurposed-drug-that/)
- [Laparoscopic Forceps with Force Feedback](https://scholariq.org/papers/laparoscopic-forceps-with-force-feedback/)

## University researchers

- [Toshinari Yamasaki](https://scholariq.org/researchers/toshinari-yamasaki/)

## University top topics

Showing 8 of 25.

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Acute Ischemic Stroke Management](https://scholariq.org/topics/acute-ischemic-stroke-management/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cardiac Valve Diseases and Treatments](https://scholariq.org/topics/cardiac-valve-diseases-and-treatments/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Cerebrovascular and Carotid Artery Diseases](https://scholariq.org/topics/cerebrovascular-and-carotid-artery-diseases/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.